Spero Therapeutics (NASDAQ:SPRO) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Spero Therapeutics (NASDAQ:SPRO) posted its earnings results on Monday. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01, Zacks reports. Spero Therapeutics had a net margin of 21.09% and a return on equity of 35.42%. The firm had revenue of $10.20 million during the quarter, compared to analysts’ expectations of $9.80 million. During the same period in the previous year, the company earned ($0.23) earnings per share.

Spero Therapeutics Stock Performance

Shares of Spero Therapeutics stock traded down $0.07 on Tuesday, reaching $1.27. The stock had a trading volume of 323,154 shares, compared to its average volume of 222,742. The stock has a market cap of $68.57 million, a P/E ratio of 3.08 and a beta of 0.63. Spero Therapeutics has a fifty-two week low of $0.99 and a fifty-two week high of $1.89. The business’s 50-day moving average price is $1.38 and its two-hundred day moving average price is $1.51.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on SPRO. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Spero Therapeutics in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a research report on Tuesday. Finally, TD Cowen upgraded Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.